Did Novo Nordisk Just Say "Checkmate" to Pfizer? These two leading drugmakers are fighting over a promising GLP-1 candidate.
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.
Meet the 7% Yield Dividend Stock That Could Soar in 2026 This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.
Is It Time to Dump Your Shares of Pfizer? Pfizer stock has dropped 50% over the past three years.
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
The market is filled with gapping stocks in Thursday's session. Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
2 High-Yield Stocks With Fresh Catalysts Income investors can capture yields above 5% from companies executing business transformations.
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (
NYSE: PFE ). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
2 Mega-Dividend Stocks With Yields As High As 7% Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.
Down 44%, Should You Buy the Dip on Viking Therapeutics? The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Where Will Pfizer Be in 5 Years? Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.
